Acute myeloid leukemia CAR-T cell therapy (AbelZeta Pharma)

N/A

Report date: 2024/02/28 13:13:27

Base Information

Drug NameAcute myeloid leukemia CAR-T cell therapy (AbelZeta Pharma)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCellular Biomedicine (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A